Anaphylaxis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Epinephrine, Steroids, Antihistamines, Beta-antagonists, Others), By Route of Administration (Oral, Parenteral, Others), By Application (Food Allergy, Pollen Allergy, Dust Mites Allergy, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region Forecast 2020-2031

Anaphylaxis Treatment Market size was valued at US$ 3,380.7 million in 2024 and is expected to reach US$ 6,140.5 million by 2031, growing at a significant CAGR of 8.9% from 2025-2031. Anaphylaxis is a serious allergic condition that may cause even death of the patients. Throat swelling, vomiting, shortness of breath, itchy rash, and low blood screening pressure are some symptoms of anaphylaxis. Insect bites, unwanted food consumption, and medications are some of the causes of anaphylaxis. The increasing number of allergic patients across the globe is expected to drive the growth of the anaphylaxis treatment market. For instance, about 150 million Europeans are affected by chronic allergies each year and according to the National Institute of Healthcare Excellence, more than 20 people die in the UK owing to improper treatment of anaphylaxis.

In addition, increasing research and development of anti-anaphylaxis drug quality and increasing anaphylaxis treatment market demand for self-administration treatment are anticipated to boost the growth of the anaphylaxis treatment market. Furthermore, increasing awareness about the treatment of anaphylaxis, increasing geriatric population, and rising overuse of medicines in rural areas is anticipated to have a positive impact on the growth of the anaphylaxis treatment market over the forecast period. However, side effects caused by the administration of epinephrine and steroids, and lack of knowledge in developing countries is expected to hinder the growth of anaphylaxis treatment market. Moreover, increasing investments in many countries, and increasing government support in lowering the treatment cost and increasing product approvals are anticipated to provide opportunities to the manufacturers and market players in the growth of anaphylaxis treatment market over the forecast period. 

Key Developments:

• In March 2022, Aquestive Therapeutics Inc. announced their USFDA approval of AQST-109, the first orally delivered epinephrine-based drug for the emergency treatment of allergic reactions.